亚甲蓝示踪在乳腺癌前哨淋巴结活检中的意义分析  被引量:6

Analysis of methylene blue tracer in sentinel lymph node biopsy of breast cancer

在线阅读下载全文

作  者:王合兵 肖坚 陈文新 杨炳林 WANG Hebing;XIAO Jian;CHEN Wenxin;YANG Binglin(The first Affiliated Sanming Hospital of Fujian Medical University,Sanming 365000,Fujian)

机构地区:[1]福建医科大学附属三明第一医院

出  处:《菏泽医学专科学校学报》2019年第3期33-34,80,共3页Journal of Heze Medical College

摘  要:目的探讨亚甲蓝示踪剂在乳腺癌前哨淋巴结活检中的应用价值。方法选取实施前哨淋巴结活检手术治疗的乳腺癌患者200例,随机分为观察组和对照组,每组100例。观察组实施亚甲蓝示踪活检,对照组实施纳米碳示踪剂活检,比较两组不同活检方法的结果,并分析其临床应用价值。结果两组定位成功率比较,P>0.05。两组假阳性率、假阴性率、检出率、准确率比较,P均<0.05。两组检出前哨淋巴结数量比较,P<0.05。结论临床将亚甲蓝示踪剂应用于乳腺癌前哨淋巴结活检中,可有效提升前哨淋巴结检出数量,且检出准确率高,利于乳腺癌的治疗和干预。Objective To investigate the clinical value of methylene blue tracer in sentinel lymph nodes biopsy of breast cancer.Methods 200 breast cancer patients who were admitted to our hospital for surgical treatment of sentinel lymph node biopsy were randomly divided into the observation group and the control group,100 cases in each group.The observation group used methylene blue tracer biopsy and the control group used nano carbon light tracer biopsy.The results of different biopsy methods were compared and analyzed.Results In terms of the success rate of localization,the control group was 71.00%and the observation group was 85.00%,the comparison of the two groups had no significant difference(P>0.05).The comparison of false positive rate,false negative rate,detection rate and accuracy between the two groups was P<0.05.The comparsion of detected sentinel nodes number between the two groups was P<0.05.Conclusion The clinical application of methylene blue tracer in sentinel lymph node biopsy of breast cancer can effectively increase the number of detected sentinel lymph nodes and the detection accuracy is high,which is conducive to the treatment and intervention of breast cancer.

关 键 词:乳腺癌 前哨淋巴结 亚甲蓝示踪 活检技术 

分 类 号:R322.2[医药卫生—人体解剖和组织胚胎学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象